2026-08-03Bullish
+19.00%weekly changeDexCom stock surged after reporting strong Q2 2026 earnings beats, raising full-year guidance, and showing margin expansion.
read the report →DexCom is a global leader in medical technology that pioneers continuous glucose monitoring biosensors, software, and integrated devices to transform metabolic health management.
stitched from the price window carried by each report
DexCom stock surged after reporting strong Q2 2026 earnings beats, raising full-year guidance, and showing margin expansion.
read the report →DexCom stock surged after beating Q2 2026 revenue and EPS estimates and raising its full-year guidance.
read the report →The stock rose on analyst price target upgrades, strong peer earnings from Abbott, and Canadian authorization for the Dexcom G7.
read the report →